Navigation Links
Breast Cancer Patients Take DNA Test to Determine Best Treatment
Date:10/30/2008

SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment. According to the National Foundation for Cancer Research (NFCR), this failure rate can be reduced to less than ten percent, saving 20,000 lives each year, by having patients take a simple DNA test and properly managing their medications.

Recent research shows that tamoxifen has to be activated into endoxifen by the liver enzyme CYP2D6. Endoxifen is the medicine that prevents the recurrence of estrogen receptive positive cancers.

About ten percent of breast cancer patients prescribed tamoxifen are missing CYP2D6 because of their DNA, and will fail tamoxifen treatment. "Patients want to know that tamoxifen will definitely benefit them, before committing to take it for five years. DNA testing offers them the reassurance that their tamoxifen is effective," stated Dr. Michael Benjamin, oncologist and editor of the medical news website, InteractMD.com

Breast cancer patients can also fail tamoxifen treatment by unknowingly taking other prescription drugs, herbals preparations, or over-the-counter medicines that interfere with CYP2D6 activity. Many classes of drugs, including anti-depressants, prevent CYP2D6 from converting tamoxifen into endoxifen. That's why Genelex includes password-protected access to their GeneMedRx software program with each test. Patients enter all of the drugs they take and produce a report to learn if any of the drugs they take might be defeating their endoxifen treatment.

"Patients and physicians need to be aware that DNA testing for tamoxifen effectiveness is available now. There is typically a 10-year gap between research and application in the clinical setting. We need to shorten that time when people's lives are at stake -- as they are with tamoxifen," stated Genelex founder and CEO Howard Coleman.

For more information about the CYP2D6 DNA test, visit Genelex at http://www.HealthandDNA.com, or call (800) 532-3080. Genelex donates a portion of all tests purchased to the National Foundation for Cancer Research.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... Cutting Edge ... of highly differentiated spinal implant technologies, announced today the appointment of Luke Maher ... spinal device industry experience to directing Cutting Edge Spine’s national sales force, including ...
(Date:8/22/2017)... ... 2017 , ... KBioBox is pleased to announce the creation ... ananlysis. KBioBox has adapted their core technology and direct alignment algorithms to extend ... understand reports, extended indel analysis, and translocation analysis. , “The extended GUIDE-Seq analysis ...
(Date:8/21/2017)... ... 2017 , ... MacArthur Sotheby’s International Realty, a luxury real ... the first Delos Wellness Signature™ residence in Hawaii is on the market for ... listing agent Kelly Allen, R(S) of Carvill Sotheby’s International Realty located on Oahu, ...
(Date:8/21/2017)... ... August 21, 2017 , ... Baltimore ... bio security firm, to bring its proprietary CANARY pathogen detection technology and high ... the Chinese firm has purchased an undisclosed number of PathSensors’ Zephyr pathogen detection ...
Breaking Biology Technology:
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):